Endotoxin markers in bronchoalveolar lavage fluid of patients with interstitial lung diseases by Bogumiła Szponar et al.
Szponar et al. Multidisciplinary Respiratory Medicine 2012, 7:54
http://www.mrmjournal.com/content/7/1/54ORIGINAL RESEARCH ARTICLE Open AccessEndotoxin markers in bronchoalveolar lavage
fluid of patients with interstitial lung diseases
Bogumiła Szponar1,2*, Lennart Larsson2 and Joanna Domagała-Kulawik3Abstract
Background: Exposure to inhaled endotoxins (lipopolysaccharides, LPS) of Gram-negative bacteria commonly
found in indoor environments and assessed in secondary tobacco smoke, has been associated with airway
inflammation and asthma exacerbation. The bronchoalveolar lavage fluid (BALf) from patients with interstitial lung
diseases (sarcoidosis, lung fibrosis, smoking-related ILD, eosinophilic disorders) was analyzed for the markers of
lipopolysaccharide (LPS, endotoxin).
Methods: BALf was obtained from patients with diffuse lung diseases: idiopathic pulmonary fibrosis (n = 42),
sarcoidosis (n = 22), smoking-related-ILD (n = 11) and eosinophilic disorders (n = 8). Total cell count and differential
cell count were performed. In addition, samples were analyzed for 3-hydroxy fatty acids (3-OHFAs) of 10–18 carbon
chain lengths, as markers of LPS, by gas chromatography-tandem mass spectrometry.
Results: The highest LPS concentration was found in patients with eosinophilic disorders and the lowest in patients
with sarcoidosis (p< 0.05) followed by the lung fibrosis and the sr-ILD patients. The difference between LPS in
BALf with extremely high eosinophil proportion (> 25%) and those with lower proportion was also significant
(p = 0.014). A significant correlation was found between LPS and eosinophils, but not between LPS and
lymphocytes, neutrophils, or macrophages count.
Conclusions: A positive relationship of LPS and eosinophilic pulmonary disorders may be linked to a persistent
eosinophil activation mediated by Th2 pathway: chronic endotoxin exposure would intensify Th2 pathway resulting
in fibrosis and, at the same time, eosinophil stimulation, and hence in eosinophilic pulmonary disorders.
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Exposure to inhaled endotoxins (lipopolysaccharides,
LPS), components of the cell wall of Gram-negative bac-
teria which are ubiquitous e.g. in the indoor environ-
ment, has been associated with progression of chronic
lung diseases and asthma exacerbation [1]. LPS exposure
in indoor environments is assessed by chemical markers
- 3-hydroxy fatty acids (3-OHFAs), exclusively present in
lipid A, the most conservative part of lipopolysaccharide
[2-5]. Large amounts of LPS were detected in the main-
stream and second hand cigarette tobacco smoke [6,7].
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reproduction in any medium, provided the orlavage fluid (BALf) from patients suffering from intersti-
tial lung diseases (ILD) regarding possible relationship of
endotoxin deposited in alveolar space. Endotoxin could
be an etiological agent and biomarker with potential
diagnostic application in the ILD.
We studied a relationship between LPS and cell pat-
terns in BALf from patients with smoking-related inter-
stitial lung diseases, including pulmonary fibrosis.
Patients with sarcoidosis, all non-smokers, were encom-
passed as a comparison group. The BALf examination is
decisive in smoking-related interstitial lung diseases [8]
and in sarcoidosis [9]; in other lung diseases is regarded
as a supplementary method. The usefulness of BALf
examination as low invasive and well standardized tech-
nique in the diagnosis of diffuse lung diseases was widely
documented [10-13].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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either the innate or adaptive immunity, depending on
concentration and time of exposure [14]. The endotoxin
in BALf could therefore reflect a role of air-borne LPS
(e.g. from tobacco smoke or organic dust) in initiating
the interstitial pulmonary diseases of some clinical mani-
festations. Indeed, it is widely accepted that environmen-
tal factors are important in sarcoidosis pathogenesis, as
well as in hypersensitivity pneumonitis [15,16]. In their
recent review Seibold and Schwartz [17] identified
tobacco smoke, air pollution and LPS as three key fac-
tors capable of modifying the genetic susceptibility to
lung diseases. Also, in an experimental study on idio-
pathic pneumonia after allogeneic bone marrow trans-
plantation in mice, LPS was described as the principal
agent triggering pulmonary damage by releasing inflam-
matory cytokines [18].
The role of exposure to inhalable agents, both known
(tobacco smoke, allergens) or unidentified, is strongly
considered in yet unknown aetiology of interstitial lung
disease. We aimed to analyze the relationship of endo-
toxin present in BALf of patients with different types of
well-defined ILD.
Methods
BALf was obtained from patients with diffuse lung dis-
eases. All patients gave informed consent to bronchos-
copy and sampling of BALf and the study was approved
by the Ethics Committee at the Medical University
of Warsaw (No. KB/106/2004). Eighty three individuals
in total were involved in the study, suffering from
sarcoidosis (n = 22, mean age 42 yr., range 26–73 yr.,
12 male/10 female), smoking-related interstitial lung
diseases (sr-ILD) (n = 11, mean age 53 yr., range 27–
77 yr., 8 males/3 females), eosinophilic disorders (n = 8,
mean age 53 yr., range 30–69, 3 males/5 females), and
lung fibrosis (n = 42, mean age 62 yr., range 30–80 yr.,
27 males/15 females). Diagnosis of interstitial lung dis-
eases was established according to ATS/ERS Inter-
national Multidisciplinary Consensus Classification of
the Idiopathic Interstitial Pneumonias [19]. The follow-
ing diseases were included in the group of eosinophilic
disorders: chronic eosinophilic pneumonia (CEP), Churg
Strauss Syndrome, and Wegener granulomatosis. The
large group of lung fibrosis patients included patients
with lung fibrosis in the course of hypersensitivity pneu-
monitis, with connective diseases, and with idiopathic
pulmonary fibrosis (IPF).
At the time of collecting the BAL material none of the
patients suffered from any known ongoing infection.
BALf was collected according to the guidelines of Polish
Respiratory Society [13], in line with the international
guidelines [20], using 200 mL of saline, and total and dif-
ferential cell counts were performed. The mean volumeof recovery fluid was 100 mL. Cell smears were prepared
immediately after the sample had been received at the
laboratory, according to the guidelines [13]. After filtra-
tion the fluid was centrifuged for 10 min at 400 × g,
then the cell pellet was resuspended in PBS. Superna-
tants were collected in six 5-mL tubes and frozen at
−20°C. Total cells were counted using a Bürker chamber
whereas differential cell counting was performed on
slides stained with the May-Grünwald-Giemsa method.
Three hundred cells were used for differential cell count-
ing. The proportion and number of alveolar macro-
phages (AM), lymphocytes (L), polymorphonuclear
granulocytes (PMN) and eosinophils (Eo) were calcu-
lated. The smears of all samples were stained with
haematoxylin-eosin and interference from any possible
malignant cells was excluded. The presence of any ab-
normal constituents (cells, acellular material, microor-
ganisms) was studied by using light microscopy
(magnification × 1000).
BALf supernatants were lyophilized, weighted, and
prepared for analysis. In brief, samples were heated in
2 M methanolic HCl at 80°C 18 hours. The liberated
fatty acid methyl esters were extracted with heptane and
the hydroxylated fatty acid methyl esters were purified
by solid phase extraction as previously described [21].
Prior to analysis, the hydroxy fatty acid methyl esters
were transformed to trimethylsilyl ethers. Samples
thus obtained were kept at 4°C until analysis by
gas chromatography-tandem mass spectrometry (GC-
MSMS) as described previously [22]. Internal standard
was added to quantify the data [23].
Apart from BALf supernatants we also analyzed BALf
cell pellets in five samples from patients with different
lung diseases.
Statistical analysis
The Kruskal-Wallis test was applied for data compari-
sons, since the data were non-normally distributed, and
the Spearman rank test was applied for data correlations.
Statistical significance was set at p < 0.05.
Results
No bacteria or other microbes were found in any of the
cell smears.
Total and differential cell counts in BALf
The total cell count was highest in the sr-ILD patients
and lowest in the sarcoidosis patients (Table 1). Alveolar
macrophages (AM) predominated in all patient groups
(particularly in the sr-ILD patients) except in the
patients with eosinophilic disorders where eosinophils
accounted for as much as 51% of the studied cells.
Notably, eosinophils accounted only for 0.6 – 2% of
Table 1 Total and differential cell count in BALf from patients with interstitial lung diseases
TCC [x106] AM [%] L [%] PMN [%] Eo [%]
sarcoidosis n= 22 19 (12–25) 47 (33–60) 36 (24–56) 6 (4–11) 0.6 (0–2)
lung fibrosis n=42 29 (18–40) 48 (30–81) 15 (2–33) 10 (5–25) 4 (1–14)
sr-ILD1n=11 59 (30–68) 93 (90–94) 2 (1–4) 2 (1.5-3) 2 (1–6)
eosinophilic disorders n=8 22 (13–31) 13.5 (7.5-45) 6 (1.5-8.75) 8 (3.25-17) 51 (37–82)
1Smoking-related ILD.
Data expressed as median (p25-p75).
AM, alveolar macrophages; Eo, eosinophils; L, lymphocytes; PMN, polymorphonuclear granulocytes; TCC, Total cell count.
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for 2-10%.
Lipopolysaccharides in BALf
LPS markers were detected in all BALf samples, both in
the supernatants and the pellets. The levels of 3-OH FAs
were much higher in the pellets than in the superna-
tants, with mean values of 536 and 12.1 pmol LPS/mg,
respectively.
Patients with sarcoidosis presented the lowest concen-
trations of LPS in the BALf supernatants followed by the
lung fibrosis and the sr-ILD patients. The highest con-
centrations were found in patients with eosinophilic dis-
orders (Table 2, Figure 1). The differences between
levels of LPS in BALf from patients with sarcoidosis and
those with eosinophilic disorders were statistically sig-
nificant (p < 0.05).
Concerning the distribution in relation to cell type
predominance in BALf samples (lymphocytes higher
than normal value 20%, neutrophils higher than 5%, and
eosinophils higher than 0.5%), we found a significant in-
crease in LPS in samples with elevated proportions of
eosinophils (p = 0.003).
The BALf sample contains cellular and soluble compo-
nents from distal airways and alveolar space, and the dif-
ferential inflammatory cell count serves as a basis for
the diagnosis. Typical cells are alveolar macrophages,
lymphocytes, neutrophils and eosinophils (normal
values: > 80%, < 20%, < 5% and < 0.5%, respectively).
The difference between LPS in BALf with extremely
high eosinophil proportion (> 25%) and those with lower
proportion (< 25%) was also significant (median value
15.6 vs 8.0 pg/ml, p = 0.014). Moreover, a significantTable 2 LPS (pmol/mg) in supernatants of BAL from
patients with interstitial pulmonary disorders
n endotoxin [median] p25 p75
sarcoidosis 22 6.61* 3.68 10.43
lung fibrosis 42 8.91 6.53 13.12
sr-ILD1 11 11.68 7.16 19.09
eosinophilic disorders 8 27.88* 11.05 49.45
1 smoking related interstitial lung diseases.
*significant difference in Kruscal Wallis test.
P < 0.05.correlation of the percentage (R = 0.37, p < 0.05) and the
total number (R = 0.35, p < 0.05) of eosinophils with
endotoxin concentration was observed (Figure 2).
No significant correlation between LPS and lympho-
cytes, neutrophils, or macrophages count was observed.
A significant negative correlation between LPS and the
proportion of macrophages was found (R = −0.25, p <
0.05) (Figure 3).
Discussion
Here we report for the first time the endotoxin load in
BALf of patients with different interstitial lung diseases
including those involving the cigarette tobacco smoke
exposure. Earlier reports on the presence of airborne
endotoxin in tobacco smoke [6,24] provided the ration-
ale for the study; notably, LPS is one of the strongest
biological triggers of inflammation. The determination
of chemical markers of endotoxin has been proven to ac-
curately assess LPS levels in complex biological matrices,
and it, for the first time, was here applied in BALf
supernatants.
Patients with lung fibrosis, sarcoidosis, smoking-
related interstitial lung diseases and eosinophilic disor-
ders were involved in the study, and LPS markers were
detected in all BALf samples. Among all patients, sar-
coidosis (a disease not associated with tobacco smoking)
appeared to be the least related to the level of LPS in
BALf, while patients with sr-ILD, a disease associated
with smoking, revealedhigherLPS concentrations, and
the largest group – the pulmonary fibrosis patients -
presented median LPS concentrations in BALf. We
found significantly higher BALf LPS concentrations in
cases of eosinophilic disorders, demonstrated both as eo-
sinophil proportion and number (Table 2, Figure 1).
Neutrophils, macrophages and lymphocytes are typic-
ally the most significant inflammatory cells found in the
airways of patients with COPD, while eosinophils may
play a role in triggering inflammation in early COPD
[25]. The association between LPS and eosinophils found
in the present study is important since eosinophils in
blood are responsible for activation and perpetuation of
allergic inflammatory reactions. The normal proportion
of eosinophils in BALf cell smear is 0.5%; eosinophilic
disorders are recognized when the proportion is rising
Figure 1 LPS in BALf supernatants. Data expressed as median values (lines); ed, eosinophilic disorders; f, fibrosis; s, sarcoidosis; sr-ILD, smoking
related interstitial lung diseases.
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reported elevated percentages over normal value in 22%
of patients with ILD. The mean recorded percentages
were 1.9% in sarcoidosis, 3.9% in hypersensitivity pneu-
monitis, and 4.5% in IPF.
Surprisingly, there was no correlation of LPS with pro-
portion or absolute number of neutrophils, although it
has previously been shown that in healthy volunteers
LPS inhalation causes a marked increase in circulating
neutrophils and a moderate increase in monocytes/
macrophages or lymphocytes [28]. Also, an increase inFigure 2 Correlation of LPS with proportion of eosinophils (significanneutrophils, but not in monocytes/macrophages or lym-
phocytes, was observed in BALf three hours after inhal-
ation [29]. The negative relation of LPS to macrophages
(R = −0.25, p < 0.05) in our study may reflect an absence
of any current inflammatory reaction with endotoxin in-
volvement, because macrophages are mostly active in
the initial recognition of LPS by CD14 receptors, trigger-
ing epithelial cells to inflammatory response [30]. In
chronic exposure to environmental endotoxin the role of
lung macrophages is more complex, i.e. promoting
phagocytic activity. In case of long-time exposure tot in Spearman test).
Figure 3 Negative correlation of alveolar macrophages proportion with LPS in BAL (R = −0.25, p < 0.05).
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http://www.mrmjournal.com/content/7/1/54airborne endotoxin (i.e. in a working environment or
tobacco smoke) the defending role of macrophages is
mostly limited to phagocytosis. It can result in decreased
number and proportion of macrophages recorded in
BALf in chronic lung diseases, especially in a context of
vast eosinophils migration into the lungs.Conclusions
Local instillation of LPS to the airways causes an acute
increase in inflammatory mediators and cells [14],
whereas chronic (e.g. environmental) exposure to endo-
toxin may affect regulatory system through dendritic
cells and T regulatory cells, balancing the Th1>Th2
dependent immune response. Along with this interpret-
ation our results suggest that environmental LPS expos-
ure (i.e. occupational exposure, tobacco smoke and ETS)
represents a new, important factor in the pathogenesis
of interstitial diseases [1]. Noteworthy, the Th2 pathway
strongly promotes lung fibrosis, and sarcoidosis was re-
cently recognized to be a Th1/Th17 disorder [31,32]. As
the persistent eosinophil activation is mediated by Th2
pathway, we postulate that prolonged endotoxin expos-
ure exacerbates Th2 pathway resulting in fibrosis and, at
the same time, eosinophil stimulation. Such a mechan-
ism would explain the simultaneous increase of endo-
toxin and eosinophils in BALf.
Studies on the role on prolonged endotoxin exposure
in relation to various interstitial lung disorders will be
continued, especially regarding the role that LPS plays as
a potent stimulator of the inflammatory response and a
ligand to Toll-like receptor 4, critical in human innate
immunity of respiratory system.Abbreviations
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